doi:10.1159/000517771

[1]

Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351–9.

doi: 10.1038/ncb3124

[2]

Dang CV. Links between metabolism and cancer. Genes Dev. 2012;26(9):877–90.

doi: 10.1101/gad.189365.112

[3]

Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010;18(6):884–901.

doi: 10.1016/j.devcel.2010.05.012

[4]

Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 2019;30(3):434–46.

doi: 10.1016/j.cmet.2019.08.013

[5]

Lyssiotis CA, Kimmelman AC. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 2017;27(11):863–75.

doi: 10.1016/j.tcb.2017.06.003

[6]

Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology. 2004;80(6):394–424.

doi: 10.1159/000085237

[7]

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5): 646–74.

doi: 10.1016/j.cell.2011.02.013

[8]

DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11–20.

doi: 10.1016/j.cmet.2007.10.002

[9]

Romero-Garcia S, Lopez-Gonzalez JS, BáezViveros JL, Aguilar-Cazares D, Prado-Garcia H. Tumor cell metabolism: an integral view. Cancer Biol Ther. 2011;12:939–48.

doi: 10.4161/cbt.12.11.18140

[10]

Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.

doi: 10.1126/science.123.3191.309

[11]

Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269–70.

doi: 10.1126/science.124.3215.269

[12]

Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–9.

doi: 10.1038/nrc1478

[13]

Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277(26):23111–5.

doi: 10.1074/jbc.M202487200

[14]

He C, Jiang H, Geng S, Sheng H, Shen X, Zhang X, et al. Expression and prognostic value of c-Myc and Fas (CD95/APO1) in patients with pancreatic cancer. Int J Clin Exp Pathol. 2014;7(2):742.

[15]

de Souza CRT, Leal MF, Calcagno DQ, Costa Sozinho EK, Borges Bdo N, Montenegro RC, et al. MYC deregulation in gastric cancer and its clinicopathological implications. PloS One. 2013;8(5):e64420.

doi: 10.1371/journal.pone.0064420

[16]

Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer’s stygian link to the “Warburg Effect” and a pivotal target for effective therapy. Semin Cancer Biol. 2009;19:17–24.

doi: 10.1016/j.semcancer.2008.11.006

[17]

Wang P, Mai C, Wei YL, Zhao JJ, Hu YM, Zeng ZL, et al. Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer. Med Oncol. 2013;30(2):552.

doi: 10.1007/s12032-013-0552-5

[18]

Kwee SA, Hernandez B, Chan O, Wong L. Choline kinase alpha and hexokinase-2 protein expression in hepatocellular carcinoma: association with survival. PLoS One. 2012; 7(10):e46591.

doi: 10.1371/journal.pone.0046591

[19]

Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol. 2008;33(5):1047–54.

[20]

Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol. 2007;59(4):495–505.

doi: 10.1007/s00280-006-0291-9

[21]

Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230–3.

doi: 10.1038/nature06734

[22]

Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452(7184):181–6.

doi: 10.1038/nature06667

[23]

Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150(4):685–96.

doi: 10.1016/j.cell.2012.07.018

[24]

Wu S, Le H. Dual roles of PKM2 in cancer metabolism. Acta Biochim Biophys Sin. 2013; 45(1):27–35.

doi: 10.1093/abbs/gms106

[25]

Zhang X, He C, He C, Chen B, Liu Y, Kong M, et al. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2013; 209(8):510–5.

doi: 10.1016/j.prp.2013.06.005

[26]

Wu J, Hu L, Chen M, Cao W, Chen H, He T. Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies. Onco Targets Ther. 2016;9:4277.

doi: 10.2147/OTT.S106508

[27]

Li T, Han J, Jia L, Hu X, Chen L, Wang Y. PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation. Protein Cell. 2019;10(8):583–94.

doi: 10.1007/s13238-019-0618-z

[28]

Tang JC, Zhao J, Long F, Chen JY., Mu B, Jiang Z, et al. Efficacy of Shikonin against esophageal cancer cells and its possible mechanisms in vitro and in vivo. J. Cancer. 2018; 9(1):32.

doi: 10.7150/jca.21224

[29]

Li W, Zhang C, Ren A, Li T, Jin R, Li G, et al. Shikonin suppresses skin carcinogenesis via inhibiting cell proliferation. PLoS One. 2015; 10(5):e0126459.

doi: 10.1371/journal.pone.0126459

[30]

Hur H, Xuan Y, Kim YB, Lee G, Shim W, Yun J, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target. Int J Oncol. 2013;42(1):44–54.

doi: 10.3892/ijo.2012.1687

[31]

Lu CW, Lin SC, Chien CW, Lin SC, Lee CT, Lin BW, et al. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol. 2011;179(3):1405–14.

doi: 10.1016/j.ajpath.2011.05.050

[32]

Tong J, Xie G, He J, Li J, Pan F, Liang H. Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol. 2011;2011: 740564.

[33]

Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer. 2013; 108(1):72–81.

doi: 10.1038/bjc.2012.559

[34]

Moreno-Sánchez R, Marín-Hernández A, Gallardo-Pérez JC, Quezada H, Encalada R, Rodríguez-Enríquez S, et al. Phosphofructokinase type 1 kinetics, isoform expression, and gene polymorphisms in cancer cells. J Cell Biochem. 2012;113:1692–703.

doi: 10.1002/jcb.24039

[35]

Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA, et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science. 2012;337(6097):975–80.

doi: 10.1126/science.1222278

[36]

Vora S, Halper JP, Knowles DM. Alterations in the activity and isozymic profile of human phosphofructokinase during malignant transformation in vivo and in vitro: transformation-and progression-linked discriminants of malignancy. Cancer Res. 1985;45: 2993–3001.

[37]

Niki T, Tsutsui S, Hirose S, Aradono S, Sugimoto Y, Takeshita K, et al. Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J Biol Chem. 2009;284(47): 32344–52.

doi: 10.1074/jbc.M109.035196

[38]

Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269(38):23757–63.

doi: 10.1016/S0021-9258(17)31580-6

[39]

Zhu W, Ye L, Zhang J, Yu P, Wang H, Ye Z, et al. PFK15, a small molecule inhibitor of PFKFB3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer. PLoS One. 2016;11(9):e0163768.

doi: 10.1371/journal.pone.0163768

[40]

Korkeila E, Jaakkola PM, Syrjänen K, Pyrhönen S, Sundström J. Pronounced tumour regression after radiotherapy is associated with negative/weak glucose transporter-1 expression in rectal cancer. Anticancer Res. 2011;31(1):311–5.

[41]

Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ, Kay EW. GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer. 2009; 125(12):2778–82.

doi: 10.1002/ijc.24693

[42]

Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92:634–41.

doi: 10.1002/1097-0142(20010801)92:3<634::AID-CNCR1364>3.0.CO;2-X

[43]

Sawayama H, Ishimoto T, Watanabe M, Yoshida N, Baba Y, Sugihara H, et al. High expression of glucose transporter 1 on primary lesions of esophageal squamous cell carcinoma is associated with hematogenous recurrence. Ann Surg Oncol. 2014;21(5):1756–62.

doi: 10.1245/s10434-013-3371-1

[44]

Kitamura K, Hatano E, Higashi T, Narita M, Seo S, Nakamoto Y, et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol. 2011;55(4):846–57.

doi: 10.1016/j.jhep.2011.01.038

[45]

Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15(21): 6479–83.

doi: 10.1158/1078-0432.CCR-09-0889

[46]

Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM. Is the hypoxia-inducible factor pathway important in gastric cancer? Eur J Cancer. 2005;41(18):2792–805.

doi: 10.1016/j.ejca.2005.09.008

[47]

Röhrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732.

doi: 10.1038/nrc.2016.89

[48]

Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000;16(3):202–8.

doi: 10.1016/S0899-9007(99)00266-X

[49]

de Cedrón MG, de Molina AR. Precision nutrition to target lipid metabolism alterations in cancer. Prec Med Invest Pract Prov. 2020: 291–9.

[50]

Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498.

doi: 10.1038/nm.2492

[51]

Yarla NS, Bishayee A, Sethi G, Reddanna P, Kalle AM, Dhananjaya BL, et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol. 2016.

[52]

Li S, Qiu L, Wu B, Shen H, Zhu J, Zhou L, et al. TOFA suppresses ovarian cancer cell growth in vitro and in vivo. Mol Med Rep. 2013;8(2):373–8.

doi: 10.3892/mmr.2013.1505

[53]

Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a metaanalysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16(12): 2533–47.

doi: 10.1158/1055-9965.EPI-07-0708

[54]

Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97(7):1005–8.

doi: 10.1038/sj.bjc.6603932

[55]

Dobbins M, Decorby K, Choi BCK. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med. 2013;2013:1.

[56]

Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5:e189.

doi: 10.1038/oncsis.2015.49

[57]

Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005; 24(41): 6314–22.

doi: 10.1038/sj.onc.1208773

[58]

Qian X, Hu J, Zhao J, Chen H. ATP citrate lyase expression is associated with advanced stage and prognosis in gastric adenocarcinoma. Int J Clin Exp Med. 2015;8(5):7855.

[59]

Zhou Y, Bollu LR, Tozzi F, Ye X, Bhattacharya R, Gao G, et al. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol Cancer Ther. 2013;12(12):2782–91.

doi: 10.1158/1535-7163.MCT-13-0098

[60]

Watson JA, Fang M, Lowenstein JM. Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. Arch Biochem Biophys. 1969;135(1): 209–17.

[61]

Moffett SA, Bhandari AK, Ravindranath B. Hydroxycitric acid concentrate and food products prepared therefrom. Google Patents. 1997.

[62]

Wei J, Tong L. Crystal structure of the 500-kDa yeast acetyl-CoA carboxylase holoenzyme dimer. Nature. 2015;526(7575): 723–7.

doi: 10.1038/nature15375

[63]

Fang W, Cui H, Yu D, Chen Y, Wang J, Yu G. Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol. 2014; 31(7):15.

doi: 10.1007/s12032-014-0015-7

[64]

Calvisi DF, Frau M, Tomasi ML, Feo F, Pascale RM. Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: novel insights from interspecies comparison. Biochim Biophy Acta. 2012; 1826(1):215–37.

[65]

Nishi K, Suzuki K, Sawamoto J, Tokizawa Y, Iwase Y, Yumita N, et al. Inhibition of fatty acid synthesis induces apoptosis of human pancreatic cancer cells. Anticancer Res. 2016; 36(9):4655–60.

doi: 10.21873/anticanres.11016

[66]

Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A. 2004;101(29): 10715–20.

doi: 10.1073/pnas.0403390101

[67]

Wang H, Xi Q, Wu G. Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway. Cancer Med. 2016;5(7):1599–606.

doi: 10.1002/cam4.711

[68]

Hiraga T, Ito S, Nakamura H. Cancer stemlike cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013;73(13):4112–22.

doi: 10.1158/0008-5472.CAN-12-3801

[69]

Gu L, Zhu Y, Lin X, Lu B, Zhou X, Zhou F, et al. The IKKβ-USP30-ACLY axis controls lipogenesis and tumorigenesis. Hepatology. 2021;73(1):160–74.

doi: 10.1002/hep.31249

[70]

Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010;6(4):551–62.

doi: 10.2217/fon.10.11

[71]

Pizer ES, Wood FD, Heine HS, Romantsev FE, Pasternack GR, Kuhajda FP. Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 1996;56(6):1189–93.

[72]

Murata S, Yanagisawa K, Fukunaga K, Oda T, Kobayashi A, Sasaki R, et al. Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice. Cancer Sci. 2010;101(8):1861–5.

doi: 10.1111/j.1349-7006.2010.01596.x

[73]

Shiragami R, Murata S, Kosugi C, Tezuka T, Yamazaki M, Hirano A, et al. Enhanced antitumor activity of cerulenin combined with oxaliplatin in human colon cancer cells. Int J Oncol. 2013;43(2):431–8.

doi: 10.3892/ijo.2013.1978

[74]

Duan J, Chen L, Zhou M, Zhang J, Sun L, Huang N, et al. MACC1 decreases the chemosensitivity of gastric cancer cells to oxaliplatin by regulating FASN expression. Oncol Rep. 2017;37(5):2583–92.

doi: 10.3892/or.2017.5519

[75]

Ma S, Sun W, Gao L, Liu S. Therapeutic targets of hypercholesterolemia: HMGCR and LDLR. Dmso. 2019;12:1543–53.

doi: 10.2147/DMSO.S219013

[76]

Gray RT, Loughrey MB, Bankhead P, Cardwell CR, McQuaid S, O'Neill RF, et al. Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study. Br J Cancer. 2017;116(12):1652–9.

doi: 10.1038/bjc.2017.139

[77]

Che L, Chi W, Qiao Y, Zhang J, Song X, Liu Y, et al. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut. 2020;69(1):177–86.

doi: 10.1136/gutjnl-2018-317581

[78]

Shi J, Zhu J, Zhao H, Zhong C, Xu Z, Yao F. Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma. Tumour Biol. 2013;34(1):429–35.

doi: 10.1007/s13277-012-0567-0

[79]

Zhong C, Fan L, Yao F, Shi J, Fang W, Zhao H. HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumour Biol. 2014;35(5):4123–9.

doi: 10.1007/s13277-013-1539-8

[80]

Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J Natl Cancer Inst. 2004;96(24):1805–6.

doi: 10.1093/jnci/96.24.1805

[81]

Price DT, Coleman RE, Liao RP, Robertson CN, Polascik TJ, DeGrado TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168(1):273–80.

doi: 10.1016/S0022-5347(05)64906-3

[82]

Effert PJ, Bares R, Handt S, Wolff JM, Büll U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996;155(3):994–8.

doi: 10.1016/S0022-5347(01)66366-3

[83]

Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta. 2011;1807(6):726–34.

doi: 10.1016/j.bbabio.2010.10.022

[84]

Toshima T, Shirabe K, Matsumoto Y, Yoshiya S, Ikegami T, Yoshizumi T, et al. Autophagy enhances hepatocellular carcinoma progression by activation of mitochondrial β-oxidation. J Gastroenterol. 2014;49(5):907–16.

doi: 10.1007/s00535-013-0835-9